Enhanced platelet activation by prolactin in patients with ischemic stroke

Thrombosis and Haemostasis

Volumn 96, Issue 1, 2006, Pages 38-44

  Wallaschofski, Henri ^a   Lohmann, Tobias ^b   Hild, Eva ^b   Kobsar, Anna ^b   Siegemund, Annelie ^c   Spilcke Liss, E ^a   Hentschel, Betina ^c   Stumpf, Christian ^d   Daniel, Werner G ^d   Garlichs, Christian D ^d   Eigenthaler, Martin ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CD62p; Leptin; Platelets; Prolactin; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; LEPTIN; PADGEM PROTEIN; PROLACTIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEART ATRIUM FIBRILLATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERPROLACTINEMIA; HYPERTENSION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENICITY; THROMBOPHILIA; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LEPTIN; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PROLACTIN; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; TICLOPIDINE;

EID: 33746726412     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-09-0634     Document Type: Article

References (54)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Fisher M, Levine P, Fullerto A, et al. Marker proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol 1982; 39: 692-5.
3. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47: 1075-9.
4. Joseph R, D'Andrea G, Oster S, et al. Whole blood platelet function in acute ischemic stroke: importance of dense body secretion and effects of antithrombotic agents. Stroke 1989; 20: 38-44.
5. Toghi H, Suzuki H, Tamura K, et al. Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. Stroke 1991; 22: 17-22.
6. Grau A, Ruf A, Vogt A, et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998; 80: 298-301.
7. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999; 81: 373-7.
8. Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-4.
9. Beamer NB, Coull BM, Clark WM, et al. Persistent inflammatory response in stroke survivors. Neurology 1998; 50: 1722-8.
10. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001; 32: 133-8.
11. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-24.
12. Grau A, Buggle F, Becher H, et al. The association of leucocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996; 82: 245-55.
13. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
14. Wallaschofski H, Donne M, Eigenthaler M, et al. Prolactinas a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001; 86: 5912-9.
15. Wallaschofski H, Kobsar A, Koksch M, et al. Prolactin receptor signaling during platelet activation. Horm Metab Res 2003; 35: 228-35.
16. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-9.
17. Konstantinidis S, Schäfer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggest a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
18. Soderberg S, Ahren B, Stegmayr B, et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999; 30: 328-37.
19. Soderberg S, Stegmayr B, Ahlbeck-Glader C, et al. High leptin levels are associated with stroke. Cerebrovasc Dis 2003; 15: 63-9.
20. Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and longterm survival in ischemic stroke subtypes: a population-based study. Stroke 2001; 32: 2735-40.
21. Adams HP, Bendixen BH, Kappelle LJ, et al., for the TOAST Investigators. Classification of subtype of acute stroke: definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41.
22. Wallaschofski H, Kobsar A, Sokolova O, et al. Differences in platelet activation by prolactin and leptin. Horm Metab Res 2004; 36: 453-7.
23. Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335: 768-74.
24. Biswas S, Rodeck CH. Plasma prolactin levels during pregnancy. Br J Obstet Gynaecol 1976; 83:683-7.
25. Boyar RM, Finkelstein JW, Kapen S, et al. Twenty-four hour prolactin (PRL) secretory patterns during pregnancy. J Clin Endocrinol Metab 1975; 40: 1117-20.
26. Rolih CA, Ober KP. Pituitary apoplexy. Endocrinol Metab Clin North Am 1993; 22: 291-302.
27. Masago A, Ueda Y, Kanai H, Nagai H, Umemura S. Pituitary apoplexy after pituitary function test: a report of two cases and review of the literature. Surg Neurol 1995; 43: 158-64.
28. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.
29. Foley PW, Irvine CD, Standen GR, et al. Activated protein C resistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg 1997; 5: 157-60.
30. Gaustadnes M, Rudiger N, Moller J, et al. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis 1999; 10: 251-9.
31. Marder VJ, Matei DE. Hereditary and acquired thrombophilic syndromes. In: Hemostasis and thrombosis: basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 1243-76.
32. Libby P, Simon DI. Thrombosis and atherosclerosis. In: Hemostasis and thrombosis: basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 743-52.
33. Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol 2000; 23 (Suppl 6): VI-3.
34. Sueishi K, Ichikawa K, Kato K, et al. Atherosclerosis: coagulation and fibrinolysis. Semin Thromb Hemost 1998; 24: 255-60.
35. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997; 8: 320-8.
36. FitzGerald GA, Tigges J, Barry P, et al. Markers of platelet activation and oxidant stress in atherothrombotic disease. Thromb Haemost 1997; 78: 280-4.
37. Drouet L, Mazoyer E, Bal dit Sollier C, et al. Participation des mécanismes de la thrombose et de l'hémostase aux étapes initiales de l'athérosclérose. Arch Mal Coeur Vaiss 1998; 91: 41-51.
38. Koenig W, Rothenbacher D, Hoffmeister A, et al. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 2001; 21: 1701-5.
39. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
40. Celi A, Lorenzet, R, Furie B, et al. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin Hematol 1997; 34: 327-35.
41. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102: 1931-6.
42. Pulmonary Embolism Prevention trial. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
43. Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ 1994; 309: 1215-7.
44. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 235-46.
45. Lande K, Os I, Kjeldsen SE, et al. Effect of dopamine and dopamine-antagonist infusion on blood platelet count, size and release reaction in hypertensive and normotensive subjects. Scand J Clin Lab Invest 1989; 49: 307-15.
46. Abbott RD, Curb JD, Rodriguez BL, et al. Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. J Clin Epidemiol 2003; 56: 479-86.
47. Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol 1998; 157: 187-97.
48. Morales T, Sawchenko PE. Brainstem prolactin-releasing peptide neurons are sensitive to stress and lactation. Neuroscience 2003; 121: 771-8.
49. Culebras A, Miller M. Dissociated patterns of nocturnal prolactin, cortisol, and growth hormone secretion after stroke. Neurology 1984; 34: 631-6.
50. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
51. Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients? Stroke 2001; 32: 2948-9.
52. Caplan LR. Thoughts evoked by MATCH and other trials. Stroke 2004, 35: 2604-5.
53. Holmes MB, Sobel BE, Howard DB, et al. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999; 95: 75-82.
54. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176-85.